AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
SINTX Technologies Price Target Adjusted to $28.00, 'Buy' Rating Maintained
ByAinvest
Sunday, Jun 1, 2025 2:35 pm ET1min read
Ascendiant Capital analyst Edward Woo maintained a "Buy" rating for SINTX Technologies (SINT) with a revised price target of $28.00, a 6.67% decrease from the previous $30.00 target. Woo remains optimistic about the company's future prospects, despite the adjustment. The average target price for SINTX Technologies is $30.00, with an upside of 975.27% from the current price of $2.79. The estimated GF Value for SINTX Technologies in one year is $0.69, suggesting a 75.27% downside from the current price.
Ascendiant Capital analyst Edward Woo has maintained a "Buy" rating for SINTX Technologies (SINT), despite adjusting the price target to $28.00, a 6.67% decrease from the previous $30.00 target. This decision reflects a cautious yet optimistic view of the company's future prospects [1].The average one-year price target for SINTX Technologies is $30.00, suggesting an impressive potential upside of 975.27% from the current price of $2.79. However, GuruFocus estimates a GF Value of $0.69 for SINTX Technologies in one year, indicating a significant downside of 75.27% from the current price [1].
Wall Street analysts' consensus remains largely positive, with 24 analysts setting an average one-year price target of $115.21 for Gilead Sciences Inc (GILD), suggesting a potential upside of 4.66% from the current share price of $110.08. This optimism is reflected in the "Outperform" consensus rating from 30 brokerage firms [2].
Despite the optimistic projections, GuruFocus' GF Value estimate for Gilead Sciences Inc (GILD) in one year is $83.69, predicting a potential downside of 23.97% from the current price of $110.08. This discrepancy highlights a cautious appraisal of the stock's fair trading value [2].
References:
[1] https://www.gurufocus.com/news/2898024/sintx-technologies-sint-rating-maintained-as-price-target-adjusted-sint-stock-news
[2] https://www.gurufocus.com/news/2899947/gilead-sciences-gild-reports-positive-results-for-trodelvy-combo-in-breast-cancer-study
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet